GE HealthCare (Nasdaq: GEHC) today announced that the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ®) for ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access information on a device and to provide personalised ads and content, ad and ...

The FDA greenlit marketing for the first blood test to help diagnose Alzheimer’s disease. Experts believe this will increase ...

However, this method cannot visualize the metabolic activity of tumor cells. That is why amino acid positron emission tomography (amino acid PET) is increasingly being used in research, but also in ...

Brain metastases often occur as a result of advanced cancer, and despite medical ... and therapy monitoring. A special imaging procedure, amino acid PET, can not only improve patient care, but ...

Brain metastases often occur as a result of advanced cancer and ... diagnostics and therapy monitoring. A special imaging procedure, amino acid PET, can not only improve patient care, but also ...

This led to further testing—including a CT scan, biopsy, and PET scan ... no new cancer. Instead, it was paraneoplastic cerebellar syndrome, where antibodies attacked my brain.

However, difficulty with distinguishing between tumor extent and treatment-induced changes such as radiation necrosis limits imaging of the extent of contrast ... in determining the size and location ...

There is currently no FDA-approved targeted amino acid PET agent for brain cancer imaging available in the US. TLX101-CDx was previously granted Orphan Drug and Fast Track designations by the FDA.

TLX101-CDx is an investigational PET imaging agent that targets the membrane transport proteins LAT1 and LAT2. It has orphan drug and fast track designations from the FDA. In the CRL, the FDA ...